Wednesday, 7 July 2021

Von Willebrand disease (VWD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030


Indication name: Von Willebrand disease (VWD)

Von Willebrand disease (VWD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Von Willebrand disease (VWD) is a blood disorder in which the blood does not clot properly. VWD is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls, which help form a platelet plug during the clotting process. The VWF gene is located on the short arm (p) of chromosome 12 (12p13). The VWF gene regulates (encodes) VWF. Mutations to this gene result in low levels of VWF, or in VWF that is defective and doesn’t function properly.

Classification-

Type 1- most common and mildest form of VWD, low levels of factor VIII, about 85% of people treated for VWD have Type 1.

Type 2- the body makes normal amounts of the VWF but the factor does not work the way it should, four subtypes― 2A, 2B, 2M, and 2N―depending on the specific problem with the person’s VWF.

Type 3- most severe form of VWD, in which a person has very little or no VWF and low levels of factor VIII. Only 3% of people with VWD have Type 3.

Epidemiology- Thelansis estimates, VWD is the most common bleeding disorder, found in up to 1% of the U.S. population. This means that 3.2 million (or about 1 in every 100) people in the United States have the disease. VWD occurs among men and women equally, women are more likely to notice the symptoms because of heavy or abnormal bleeding during their menstrual periods and after childbirth.

Competitive landscape of Von Willebrand disease (VWD) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Von Willebrand disease (VWD) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Von Willebrand disease (VWD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Von Willebrand disease (VWD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No     Asset     Company           Phase

1            Factor VIII + von Willebrand factor complex         Octapharma              Launched

2            Factor VIII          Baxter   Launched

3            Alphanate          Grifols  Launched

4            Aleviate              CSL Limited        Launched

5            8Y; Factor VIII/von Willebrand Factor      Bio Products Laboratory              Launched

6            Humate-P           CSL Limited        Launched

7            von Willebrand factor    LFB        Launched

8            vonicog alfa       Baxter   Launched

9            human von Willebrand factor     China Biologic Products Phase I
 

No comments:

Post a Comment

Post-traumatic stress disorder (PTSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

  Indication name: Post-traumatic stress disorder (PTSD) Post-traumatic stress disorder (PTSD) – Market outlook, Epidemiology, Market For...